Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

NCT00418574 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
888
Enrollment
INDUSTRY
Sponsor class

Stopped No benefit on primary end point (RFS); no rationale to collect survival data

Conditions

Interventions

Sponsor

Menarini Group